Startseite Kongressberichte & Archiv All-Virtual 62nd ASH Annual Meeting and Exposition Press Briefings Press Briefing on What’s on the Horizon: Practice-Changing Clinical Trials

What’s on the Horizon: Practice-Changing Clinical Trials (Moderator - Lisa Hicks, MD, St. Michael’s Hospital)

What's on the Horizon: Practice-Changing Clinical Trials press release 

Abstracts presented:

412 Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) according to ASH clinically relevant abstract

Meletios A. Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.

Conclusion: In this phase 3 study evaluating DARA SC plus Pd, D-Pd significantly reduced the risk of progression or death by 37% in pts with RRMM who had received ≥1 prior line of therapy vs Pd alone. No new safety concerns were observed. The IRR rate was very low and administration duration short, thus increasing convenience for pts and decreasing treatment burden. Collectively, these data show that D-Pd is an effective and convenient treatment for pts with RRMM who received ≥1 prior therapy, including len and a PI.

2 Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial according to ASH clinically relevant abstract

Terry B. Gernsheimer, Siobhan P Brown, Darrell J Triulzi, et al.

Conclusion: Prophylactic TXA has no effect on the incidence of WHO Grade 2+ bleeding when given in addition to routine plt transfusions to severely thrombocytopenic patients undergoing therapy for hematologic malignancy. An increased incidence of line occlusion in the TXA arm was observed but no increase in other types of thrombotic events was detected.

16 Hospitalization and Case Fatality in Individuals with Sickle Cell Disease and COVID-19 Infection

Lana Mucalo, Amanda M. Brandow, Sadie F. Mason, et al.
 
Conclusion: Our findings show that individuals with SCD who have COVID-19 infection have higher rates of death due to COVID-19 than the general Black population. Also, a large proportion of COVID hospitalization for the SCD population occurs among the younger age group. Further analysis is planned to examine effects of underlying comorbidities and prior SCD-associated complications on the severity of COVID-19 in individuals with SCD.

75 A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102 according to ASH clinically relevant abstract

Ryotaro Nakamura, M.D.1, Wael Saber, MD, MS2, Michael J Martens, et al. and Corey Cutler

Conclusions: We observed a significant OS advantage in older patients with Int-2 and High IPSS risk de novo MDS who are RIC HCT candidates and have an HLA-matched donor, when compared with those without a donor. The benefit of having a matched donor was seen across subgroups, including those who were of Medicare age (>65) and below. HCT should be offered to all individuals between the ages of 50-75 with Int-2 and High IPSS risk MDS in whom a suitable donor can be identified.